연구동향 분석
박사

암환자의 방사선 치료 효과 증진과 예후 진단 기술 개발을 위한 환자 암조직 이식 동물 모델에서 in vivo peptide screening 및 다기능성 표적 약물 전달 시스템 구축

이경진 2015년

논문상세정보
인용/피인용
' 암환자의 방사선 치료 효과 증진과 예후 진단 기술 개발을 위한 환자 암조직 이식 동물 모델에서 in vivo peptide screening 및 다기능성 표적 약물 전달 시스템 구축' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • adenocarcinoma
  • drug delivery system
  • in vivo peptide screening
  • patient-derived xenograft (pdx)
  • peptide
  • phage display
  • radiation
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
461 0

0.0%

' 암환자의 방사선 치료 효과 증진과 예후 진단 기술 개발을 위한 환자 암조직 이식 동물 모델에서 in vivo peptide screening 및 다기능성 표적 약물 전달 시스템 구축' 의 참고문헌

  • de Bruin EC, Cowell CF, Warne PH, Jiang M, Saunders RE, Melnick MA, et al.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancerdiscovery. 2014.
  • Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, et al. Expression of miR-29c, miR-93,and miR-429 as Potential Biomarkers for Detection of Early Stage Non-Small Lung Cancer.PloS one. 2014;9(2):e87780.
  • Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert opinionon drug delivery. 2008;5(3):309-19.
  • Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use ofnanoparticles in diagnosis and treatment of breast cancer. The lancet oncology.2006;7(8):657-67.
  • Yasufuku K. Early diagnosis of lung cancer. Clinics in chest medicine. 2010;31(1):39-47, Table of Contents.
  • Yang Y, Zizheng W, Tongxin D. Mouse thymus targeted peptide isolated by in vivophage display can inhibit bioactivity of thymus output in vivo. Journal of biomolecularscreening. 2008;13(10):968-74.
  • Wu X, Chen H, Wang X. Can lung cancer stem cells be targeted for therapies?Cancer treatment reviews. 2012;38(6):580-8.
  • Weissleder R. Molecular imaging in cancer. Science. 2006;312(5777):1168-71.
  • Wang C, Zhao M, Liu YR, Luan X, Guan YY, Lu Q, et al. Suppression ofcolorectal cancer subcutaneous xenograft and experimental lung metastasis usingnanoparticle-mediated drug delivery to tumor neovasculature. Biomaterials.2014;35(4):1215-26.
  • Wang AZ, Tepper JE. Nanotechnology in radiation oncology. Journal of clinicaloncology : official journal of the American Society of Clinical Oncology. 2014;32(26):2879-85.
  • Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Geneticprognostic and predictive markers in colorectal cancer. Nature reviews Cancer.2009;9(7):489-99.
  • Vincent RG, Pickren JW, Lane WW, Bross I, Takita H, Houten L, et al. Thechanging histopathology of lung cancer: a review of 1682 cases. Cancer. 1977;39(4):1647-55.
  • Vega J, Ke S, Fan Z, Wallace S, Charsangavej C, Li C. Targeting doxorubicin toepidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamicacid) through a polyethylene glycol spacer. Pharmaceutical research. 2003;20(5):826-32.
  • Uncu D, Aksoy S, Cetin B, Yetisyigit T, Ozdemir N, Berk V, et al. Results ofadjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of667 patients. Oncology. 2013;84(4):240-5.
  • Tsuchida T, Morikawa M, Demura Y, Umeda Y, Okazawa H, Kimura H. Imagingthe early response to chemotherapy in advanced lung cancer with diffusion-weightedmagnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emissiontomography and computed tomography. Journal of magnetic resonance imaging : JMRI.2013;38(1):80-8.
  • Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Naturereviews Drug discovery. 2005;4(2):145-60.
  • Toba M, Alzoubi A, O'Neill K, Abe K, Urakami T, Komatsu M, et al. A novelvascular homing peptide strategy to selectively enhance pulmonary drug efficacy inpulmonary arterial hypertension. The American journal of pathology. 2014;184(2):369-75.
  • Tian H, Liu S, Zhang J, Zhang S, Cheng L, Li C, et al. Enhancement of cisplatinsensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmidexpressing small hairpin RNA targeting Survivin. Journal of biomedical nanotechnology.2012;8(4):633-41.
  • Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. A systematic analysis of peptidelinker length and liposomal polyethylene glycol coating on cellular uptake of peptidetargetedliposomes. ACS nano. 2013;7(4):2935-47.
  • Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging.Expert opinion on drug delivery. 2008;5(2):189-204.
  • Smith GP. Filamentous fusion phage: novel expression vectors that display clonedantigens on the virion surface. Science. 1985;228(4705):1315-7.
  • Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics:bioconjugated nanoparticles for drug delivery. Molecular cancer therapeutics.2006;5(8):1909-17.
  • Sidhu SS. Engineering M13 for phage display. Biomolecular engineering.2001;18(2):57-63.
  • Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neckcancer. Nature clinical practice Oncology. 2007;4(3):156-71.
  • Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science.1990;249(4967):386-90.
  • Schumacher TN, Tsomides TJ. In vitro radiolabeling of peptides and proteins. CurrProtoc Protein Sci. 2001;Chapter 3:Unit 3
  • Schally AV. New approaches to the therapy of various tumors based on peptideanalogues. Hormone and metabolic research = Hormon- und Stoffwechselforschung =Hormones et metabolisme. 2008;40(5):315-22.
  • Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment.Current drug delivery. 2005;2(4):369-81.
  • Santini C, Brennan D, Mennuni C, Hoess RH, Nicosia A, Cortese R, et al. Efficientdisplay of an HCV cDNA expression library as C-terminal fusion to the capsid protein D ofbacteriophage lambda. Journal of molecular biology. 1998;282(1):125-35.
  • Qi Q, Lu N, Li C, Zhao J, Liu W, You Q, et al. Involvement of RECK in gambogicacid induced anti-invasive effect in A549 human lung carcinoma cells. Molecularcarcinogenesis. 2014.
  • Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status andemerging strategies. Clinical radiology. 2010;65(7):500-16.
  • Ploss M, Facey SJ, Bruhn C, Zemel L, Hofmann K, Stark RW, et al. Selection ofpeptides binding to metallic borides by screening M13 phage display libraries. BMCbiotechnology. 2014;14(1):12.
  • Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al.Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibitingangiogenesis. Cancer research. 2000;60(3):722-7.
  • Park HY, Lee KJ, Lee SJ, Yoon MY. Screening of peptides bound to breast cancerstem cell specific surface marker CD44 by phage display. Molecular biotechnology.2012;51(3):212-20.
  • Park HY, Kim J, Cho JH, Moon JY, Lee SJ, Yoon MY. Phage display screen forpeptides that bind Bcl-2 protein. Journal of biomolecular screening. 2011;16(1):82-9.
  • Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al.Treatment of gastric cancer. World journal of gastroenterology : WJG. 2014;20(7):1635-49.
  • On the rise globally, cancer mortality declines in U.S. Cancer discovery.2014;4(3):OF7.
  • Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y.Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lungcancer. 2013;80(1):45-9.
  • Nie S. Understanding and overcoming major barriers in cancer nanomedicine.Nanomedicine (Lond). 2010;5(4):523-8.
  • Mozafari MR. Nanoliposomes: preparation and analysis. Methods in molecularbiology. 2010;605:29-50.
  • Molek P, Strukelj B, Bratkovic T. Peptide phage display as a tool for drugdiscovery: targeting membrane receptors. Molecules. 2011;16(1):857-87.
  • Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosizedvehicles for drug delivery in cancer. Trends in pharmacological sciences. 2009;30(11):592-9.
  • Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, StemmermannGN, et al. Chemoradiotherapy after surgery compared with surgery alone foradenocarcinoma of the stomach or gastroesophageal junction. The New England journal ofmedicine. 2001;345(10):725-30.
  • Liu C, Wen Z, Li Y, Peng L. Application of ThinPrep Bronchial Brushing Cytologyin the Early Diagnosis of Lung Cancer: A Retrospective Study. PloS one. 2014;9(4):e90163.
  • Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, et al. Patterns offailure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiationoncologist's view. British journal of cancer. 2004;91(1):11-7.
  • Li LL, Xie CY, Su HF. Benefit of radiotherapy on survival in resectable gastriccarcinoma: a meta-analysis. Tumour biology : the journal of the International Society forOncodevelopmental Biology and Medicine. 2014;35(5):4957-66.
  • Lee KJ, Lee JH, Chung HK, Choi J, Park J, Park SS, et al. Novel peptidesfunctionally targeting in vivo human lung cancer discovered by in vivo peptide displayedphage screening. Amino acids. 2014.
  • Lee JW, Song J, Hwang MP, Lee KH. Nanoscale bacteriophage biosensors beyondphage display. International journal of nanomedicine. 2013;8:3917-25.
  • Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practiceguidelines for gastric cancer in Korea: an evidence-based approach. Journal of gastric cancer.2014;14(2):87-104.
  • Larimer BM, Thomas WD, Smith GP, Deutscher SL. Affinity Maturation of anERBB2-Targeted SPECT Imaging Peptide by In Vivo Phage Display. Molecular imaging andbiology : MIB : the official publication of the Academy of Molecular Imaging. 2014.
  • Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variableclonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science.2013;339(6119):543-8.
  • Ko JH, Gu W, Lim I, Bang H, Ko EA, Zhou T. Ion channel gene expression in lungadenocarcinoma: potential role in prognosis and diagnosis. PloS one. 2014;9(1):e86569.
  • Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, et al. Stericallystabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells invitro. Biochemistry. 1997;36(1):66-75.
  • Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer care.Molecular oncology. 2012;6(2):182-95.
  • Kipp JE. The role of solid nanoparticle technology in the parenteral delivery ofpoorly water-soluble drugs. International journal of pharmaceutics. 2004;284(1-2):109-22.
  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA: a cancer journal for clinicians 2011, 61(2):69-90.
  • Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science,rationale, and clinical applications, existing and potential. International journal ofnanomedicine. 2006;1(3):297-315.
  • Hughes C, Greywoode G, Chetty R. Gastric pseudo-signet ring cells: a potentialdiagnostic pitfall. Virchows Archiv : an international journal of pathology. 2011;459(3):347-9.
  • Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer:Classification, histology and application of molecular pathology. Journal of gastrointestinaloncology. 2012;3(3):251-61.
  • Housby JN, Mann NH. Phage therapy. Drug discovery today. 2009;14(11-12):536-40.
  • Helm F, Fricker G. Liposomal conjugates for drug delivery to the central nervoussystem. Pharmaceutics. 2015;7(2):27-42.
  • Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet.2009;374(9688):477-90.
  • Haberkorn U, Schoenberg SO. Imaging of lung cancer with CT, MRT and PET.Lung cancer. 2001;34 Suppl 3:S13-23.
  • Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotacticradiotherapy. Cancer. 2010;116(2):406-14.
  • Guckenberger M, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, et al.Is there a lower limit of pretreatment pulmonary function for safe and effective stereotacticbody radiotherapy for early-stage non-small cell lung cancer? Journal of thoracic oncology :official publication of the International Association for the Study of Lung Cancer.2012;7(3):542-51.
  • Ghosh D, Lee Y, Thomas S, Kohli AG, Yun DS, Belcher AM, et al. M13-templatedmagnetic nanoparticles for targeted in vivo imaging of prostate cancer. Naturenanotechnology. 2012;7(10):677-82.
  • Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligandsdesignof new molecular conjugates for imaging and therapy of cancers. Anti-cancer agentsin medicinal chemistry. 2007;7(5):552-8.
  • Foo M, Crosby T, Rackley T, Leong T. Role of (chemo)-radiotherapy in resectablegastric cancer. Clinical oncology. 2014;26(9):541-50.
  • Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature reviewsCancer. 2005;5(3):161-71.
  • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, ComberH, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in2012. European journal of cancer. 2013;49(6):1374-403.
  • Fei L, Yap LP, Conti PS, Shen WC, Zaro JL. Tumor targeting of a cell penetratingpeptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials.2014.
  • Fass L. Imaging and cancer: a review. Molecular oncology. 2008;2(2):115-52.
  • Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS nano.2009;3(1):16-20.
  • Estevez-Garcia P, Rivera F, Molina-Pinelo S, Benavent M, Gomez J, Limon ML, etal. Gene expression profile predictive of response to chemotherapy in metastatic colorectalcancer. Oncotarget. 2015;6(8):6151-9.
  • Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th editionof the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology.2010;17(6):1471-4.
  • Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclicRGD peptide for tumor targeting. Journal of drug targeting. 2004;12(5):257-64.
  • Du B, Qian M, Zhou Z, Wang P, Wang L, Zhang X, et al. In vitro panning of atargeting peptide to hepatocarcinoma from a phage display peptide library. Biochemical andbiophysical research communications. 2006;342(3):956-62.
  • Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, et al. targeted drug delivery tohepatocarcinoma in vivo by phage-displayed specific binding peptide. Molecular cancerresearch : MCR. 2010;8(2):135-44.
  • De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards.International journal of nanomedicine. 2008;3(2):133-49.
  • Danner S, Belasco JG. T7 phage display: a novel genetic selection system forcloning RNA-binding proteins from cDNA libraries. Proceedings of the National Academyof Sciences of the United States of America. 2001;98(23):12954-9.
  • Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al.Colorectal cancer. Lancet. 2010;375(9719):1030-47.
  • Cui FB, Li RT, Liu Q, Wu PY, Hu WJ, Yue GF, et al. Enhancement of radiotherapyefficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer.Cancer letters. 2014;346(1):53-62.
  • Conraux L, Pech C, Guerraoui H, Loyaux D, Ferrara P, Guillemot JC, et al. Plasmapeptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF massspectrometry profiling. PloS one. 2013;8(11):e79733.
  • Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management.American family physician. 2007;75(1):56-63.
  • Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phagetherapy. Future Microbiol. 2013;8(6):769-83.
  • Casado-Saenz E, Feliu J, Gomez-Espana MA, Sanchez-Gastaldo A, Garcia-Carbonero R, Seom. SEOM clinical guidelines for the treatment of advanced colorectalcancer 2013. Clinical & translational oncology : official publication of the Federation ofSpanish Oncology Societies and of the National Cancer Institute of Mexico.2013;15(12):996-1003.
  • Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, et al. NTerminallabeling of filamentous phage to create cancer marker imaging agents. ACS nano.2012;6(8):6675-80.
  • Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularlyannotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as aneffective therapeutic target in cetuximab-resistant colorectal cancer. Cancer discovery.2011;1(6):508-23.
  • Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specifictargeting on the biodistribution and efficacy of siRNA nanoparticles measured bymultimodality in vivo imaging. Proceedings of the National Academy of Sciences of theUnited States of America. 2007;104(39):15549-54.
  • Azzazy HM, Highsmith WE, Jr. Phage display technology: clinical applicationsand recent innovations. Clinical biochemistry. 2002;35(6):425-45.
  • Aranda E, Abad A, Carrato A, Cervantes A, Garcia-Foncillas J, Garcia Alfonso P, etal. Treatment recommendations for metastatic colorectal cancer. Clinical & translationaloncology : official publication of the Federation of Spanish Oncology Societies and of theNational Cancer Institute of Mexico. 2011;13(3):162-78.
  • Andresen H, Bier FF. Peptide microarrays for serum antibody diagnostics. Methodsin molecular biology. 2009;509:123-34.
  • Allen TM. Liposomal drug formulations. Rationale for development and what wecan expect for the future. Drugs. 1998;56(5):747-56.
  • Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature reviewsCancer. 2002;2(10):750-63.
  • Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics andpharmacodynamics of lipidic nano-particles in cancer. Anti-cancer agents in medicinalchemistry. 2006;6(6):513-23.